C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/13 (2006.01) A61K 39/395 (2006.01) A61P 31/18 (2006.01) C07K 16/28 (2006.01) C07K 16/46 (2006.01) C12N 5/10 (2006.01)
Patent
CA 2648056
This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement. The deimmunized antibodies retain the specificity of the murine mAb B4 for a receptor complex involving CD4 on the surface of the host T cells, and retain the characteristic ability of mAb B4 to neutralize primary isolates of HIV.
Lynn Shugene
Wang Chang Yi
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
United Biomedical (asia) Inc.
United Biomedical Inc.
LandOfFree
Designed deimmunized monoclonal antibodies for protection... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Designed deimmunized monoclonal antibodies for protection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Designed deimmunized monoclonal antibodies for protection... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1758830